Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Blood (2022) 140 (Supplement 1): 8503–8504.

https://doi.org/10.1182/blood-2022-158549

Published: 2022

Journal Articles

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2015) 126 (11): 1392–1394.

https://doi.org/10.1182/blood-2015-05-647420

Published: 2015

Includes: Supplemental data

Journal Articles

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Guillermo Sanz, Eva Hellstrom-Lindberg, Argyris Symeonidis, Jaroslav Cermak, Ulrich Germing, MD, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, Krzysztof Madry, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, David Bowen, Theo de Witte

Blood (2012) 120 (21): 3830.

https://doi.org/10.1182/blood.V120.21.3830.3830

Published: 2012

Journal Articles

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Raphael Itzykson, Alex Smith, Theo M. de Witte, Jackie Droste, Reinhard Stauder, Argyris Symeonidis, Eva Hellstrom-Lindberg, Guillermo Sanz, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Mette Skov-Holm, Ulrich Germing, MD, Marius MacKenzie, Odile Beyne-Rauzy, MD, PhD, Luca Malcovati, David Bowen, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 700.

https://doi.org/10.1182/blood.V120.21.700.700

Published: 2012

Journal Articles

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, MD, PhD, David Bowen, Guillermo Sanz, MD, Eva Hellström-Lindberg, Argyris Symeonidis, Jaroslav Cermak, MD, PhD, Ulrich Germing, MD, Reinhard Stauder, MD, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, MD, Mette Skov Holm, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, Theo de Witte, MD, PhD

Blood (2011) 118 (21): 2775.

https://doi.org/10.1182/blood.V118.21.2775.2775

Published: 2011

Journal Articles

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Argyris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, Reinhard Stauder, Jackie Droste, David Bowen, Theo de Witte

Blood (2010) 116 (21): 2917.

https://doi.org/10.1182/blood.V116.21.2917.2917

Published: 2010

Journal Articles

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

David Bowen, Alex Smith, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, Odile Beyne-Rauzy, Luca Malcovati, Theo de Witte

Blood (2010) 116 (21): 1867.

https://doi.org/10.1182/blood.V116.21.1867.1867

Published: 2010

Journal Articles

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

Reinhard Stauder, Alex Smith, Theo de Witte, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, David Bowen

Blood (2010) 116 (21): 3999.

https://doi.org/10.1182/blood.V116.21.3999.3999

Published: 2010

Journal Articles

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

T. M. de Witte, Alex Smith, Jackie Droste, Pierre Fenaux, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, MD, Odile Beyne Rauzy, David T. Bowen, MD

Blood (2009) 114 (22): 3811.

https://doi.org/10.1182/blood.V114.22.3811.3811

Published: 2009

Journal Articles

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios Anagnostopoulos, MD, Konstantinos Zervas, MD, Evangelos Terpos, MD, Marie Christine Kyrtsonis, MD, Argyris Symeonidis, MD, Dimitra Gika, Konstantinos Bourantas, MD, Athanasios Zomas, MD, Nikolaos Angnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3415.

https://doi.org/10.1182/blood.V106.11.3415.3415

Published: 2005

Journal Articles

Macrofocal Multiple Myeloma in Young Patients: A Distinct Entity with Favorable Prognosis.

Meletios A. Dimopoulos, MD, Anastasia Pouli, MD, Athanasios Angnostopoulos, MD, Panagiotis Repoussis, MD, Argyris Symeonidis, MD, Souzana Delimbasi, MD, Fotis Tsolakis, MD, Constantinos Zervas, MD

Blood (2005) 106 (11): 3399.

https://doi.org/10.1182/blood.V106.11.3399.3399

Published: 2005

NARROW

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Macrofocal Multiple Myeloma in Young Patients: A Distinct Entity with Favorable Prognosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only